Etanercept therapy in Rheumatic diseases

Speciality: Rheumatology


Speaker:

Dr. Anish Aggarwal - Moderator | Rheumatologist

Dr. Kiran Seth - Panelist | Rheumatologist

Dr. Gaurav Seth - Panelist | Rheumatologist

Dr. Gaurav Jain - Panelist | Rheumatologist

Description:

A warm welcome to all the medical professionals in this interesting session on etanercept therapy in rheumatic diseases

Etanercept is a biologic medication used to treat various rheumatic diseases, including rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. It works by inhibiting tumor necrosis factor (TNF), a protein involved in inflammation. By blocking TNF, Etanercept helps reduce inflammation, pain, and joint damage.

In rheumatoid arthritis, Etanercept has shown to significantly improve symptoms and slow disease progression. Patients experience relief from joint stiffness, swelling, and pain, leading to better physical function. It is often prescribed when other treatments, like methotrexate, do not provide sufficient results.

For psoriatic arthritis and ankylosing spondylitis, Etanercept also offers benefits by reducing joint inflammation and preventing further joint damage. It helps improve mobility and overall quality of life. However, long-term use requires regular monitoring, as it can increase the risk of infections and other side effects.

Overall, Etanercept provides an effective treatment option for patients with rheumatic diseases, especially when conventional therapies fall short.

Therefore, get an overall knowledge of etanercept therapy in rheumatic diseases. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions.
 

See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study opens up possibility of bespoke prostate cancer treatment

2.

Why Encouragement May Not Improve Motivation in Depression

3.

Study Finds Actionable Mutations in Brain Mets of Breast Cancer Patients

4.

A person's susceptibility to papillary thyroid cancer may be determined by variations in telomere lengthening genes.

5.

Pirtobrutinib May Be Beneficial in Follicular Lymphoma with Severe Pretreatment.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot